Trial Profile
A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Rhodes Pharmaceuticals
- 18 Apr 2021 Status changed from not yet recruiting to completed, as per results published in the Journal of the American Academy of Child and Adolescent Psychiatry
- 18 Apr 2021 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry
- 24 Aug 2016 Planned initiation date changed from 1 Feb 2016 to 1 Sep 2016.